BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing
Method Description Describes how the test is performed and provides a method-specific reference
Total RNA is extracted from the sample using the miRNeasy extraction kit (Qiagen). cDNA is made using the High Capacity cDNA Kit (Applied Biosystems). A first-round PCR is performed using primers directed against BCR and ABL1 regions to generate a long PCR product representing the translocated allele only (p210, p190, p205 or p230 transcript types) and encompassing the ABL1 region through exon 7. Second (nested) PCR amplifications are next performed to amplify the ABL1 kinase domain region using template from the first-round PCR product. Aliquots of the nested ABL1 PCR products are analyzed by Sanger sequencing and post-sequence software interpretation.(Unpublished Mayo method)
PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test